Effects of exenatide (Byetta) on liver biochemistry, liver histology and lipid metabolism in patients with non-alcoholic fatty liver disease

Trial Profile

Effects of exenatide (Byetta) on liver biochemistry, liver histology and lipid metabolism in patients with non-alcoholic fatty liver disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Jul 2008 The expected completion date for this trial has been extended from Jun 2009 to Feb 2010 as reported by ClinicalTrials.gov.
    • 20 Jul 2008 Status changed from initiating to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top